Infertility Treatment Global Market Report 2024

The global infertility treatment market has grown strongly in recent years. It will grow from $1.66 billion in 2023 to $1.81 billion in 2024 at a compound annual growth rate (CAGR) of 9.0%. The expansion observed in the historical period can be credited to increased awareness and education, evolving lifestyles and environmental influences, a rising incidence of male infertility, government initiatives and backing, as well as a shift in societal perspectives.

The global infertility treatment market is expected to see strong growth in the next few years. It will grow to $2.53 billion in 2028 at a compound annual growth rate (CAGR) of 8.8%. The anticipated growth in the forecast period is expected to stem from increased accessibility to fertility clinics, advancements in reproductive medicine, innovations in gamete and embryo culture, progress in male contraception, and a heightened emphasis on enhancing oocyte quality. Key trends in this period encompass technological strides in assisted reproductive technologies (ART), a rising prevalence of infertility, a widening age bracket for parenthood, the emergence of fertility preservation services, and interventions involving nutrition and lifestyle adjustments.

The global infertility treatment market is being driven by the consistent decline in the worldwide fertility rate. This decline, attributable to factors like delayed marriages and age-related fertility challenges, has led to a surge in demand for products addressing infertility issues in both men and women. According to the World Economic Forum's June 2022 report, global fertility rates have dropped by 50% over the past 70 years, highlighting the escalating need for infertility treatment solutions.

An increasingly significant factor influencing the infertility treatment market's growth is the rising demand for surrogacy services. Surrogacy, a method aiding individuals or couples facing fertility obstacles, involves a woman carrying and delivering a child for intended parents. Notably, in December 2022, The Australian Broadcasting Corporation reported approximately 100 Australian women annually becoming surrogates, underscoring the growing reliance on surrogacy to address infertility issues.

Technological advancements are becoming a pivotal trend shaping the landscape of the infertility treatment market. Companies in this sector are keen on developing innovative solutions to fortify their market positions. An example is Merck Specialties Pvt. Ltd.'s August 2021 launch of the Pergoveris Pen in India, designed for assisted reproductive technology. This device, housing recombinant luteinizing hormone and recombinant follicle-stimulating hormone, offers a self-administration fertility solution approved globally, ensuring safer and more precise fertility treatments.

Companies at the forefront of the infertility treatment market are actively innovating to introduce products such as pre-filled pens, aiming to minimize errors within fertility treatment processes. An instance is Merck & Co., Inc.'s August 2021 release of the Pergoveris Pen in the United States. This pen, combining freeze-dried powder and solvent, diminishes the likelihood of errors during the reconstitution process, specifically catering to patients with severe follicle-stimulating hormone and luteinizing hormone deficiencies. Notably, it's the sole pre-filled pen offering a combination of recombinant human follicle-stimulating hormone and recombinant human luteinizing hormone, significantly aiding women in advanced reproductive ages to enhance ovarian response quality.

In May 2021, the US-based digital elective care and telemedicine provider, RO, completed the acquisition of Modern Fertility for an approximate sum of $225 million. This strategic move allows RO to broaden its women's health offerings by incorporating fertility testing and reproductive health services, thereby expanding its suite of services. Modern Fertility, a reproductive healthcare company based in the US, now operates under the umbrella of RO following this acquisition.

Major companies operating in the infertility treatment market report are The Cooper Companies Inc., Cook Group Incorporated, Vitrolife AB, Thermo Fisher Scientific Inc., Esco Micro Pte. Ltd., Genea Limited, IVFtech ApS, FUJIFILM Irvine Scientific Inc., The Baker Company Inc., Kitazato Corporation, Rocket Medical PLC, IHMedical A/S, Hamilton Thorne Ltd., Carl Zeiss AG, MedGyn Products Inc., DxNow Inc., Nidacon International AB, Gynotec B.V., SAR Healthline Pvt. Ltd., InVitroCare Inc., Boston IVF, Shady Grove Fertility LLC, CCRM Fertility Co. LLC, IVI-RMA Global, Fertility Centers of Illinois, New Hope Fertility Center, Pacific Fertility Center, Houston Fertility Institute, Sher Fertility Institute, Columbia Asia Fertility Centre, Bourn Hall Fertility Clinic, Manipal Fertility, Morpheus IVF, Nova IVF Fertility, Indira IVF, Bloom Fertility Centre, Cloudnine Fertility, Oasis Fertility, Apollo Fertility, Milann Fertility Center, Fakih IVF, Procrea Fertility, The Montreal Fertility Center, The Center for Reproductive Medicine, The Reproductive Medicine Group, The Fertility Institute

North America was the largest region in the infertility treatment market in 2023. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the infertility treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the infertility treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary components constituting infertility treatment are equipment, media and consumables, and associated accessories. Equipment in this context refers to a wide range of tools, instruments, machinery, and materials employed for medical purposes in treating infertility in both genders. Various procedures, including assisted reproductive technology, artificial insemination, fertility-related surgeries, utilize a diverse array of drugs such as clomiphene citrate, letrozole, serophene, hormonal treatments, among others. Patients seeking infertility treatment typically fall into categories of female or male infertility, while end users of these treatments comprise hospitals, surgical clinics, cryobanks, and research institutes.

This report provides infertility treatment market statistics, including infertility treatment industry global market size, regional shares, competitors with an infertility treatment market share, detailed infertility treatment market segments, market trends and opportunities, and any further data you may need to thrive in the infertility treatment industry. This anomaly detection market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The infertility treatment market includes revenues earned by entities by providing fertility preservation, genetic carrier screening, egg treatment services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.